Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: Activity in platinum-resistant disease Academic Article uri icon

Overview

MeSH Major

  • Carcinoma
  • Ifosfamide
  • Mesna
  • Ovarian Neoplasms

abstract

  • Single-agent ifosfamide has modest but unequivocal activity in platinum-resistant ovarian cancer. Further studies of this drug used as a front-line agent along with an organoplatinum compound or as part of a dose-intensification program with bone marrow, peripheral stem cell, or colony-stimulating factor support are indicated. In addition, single-agent ifosfamide is a reasonable standard second-line treatment strategy in appropriately selected patients with platinum-refractory ovarian cancer.

publication date

  • December 1992

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed ID

  • 1732425

Additional Document Info

start page

  • 243

end page

  • 8

volume

  • 10

number

  • 2